Turning on/off tumor-specific CTL response during progressive tumor growth

Journal of Immunology

Volumn 175, Issue 5, 2005, Pages 3110-3116

  Huang, Yujun ^a   Obholzer, Nikolaus ^a   Fayad, Raja ^a   Qiao, Liang ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

EID: 23844527421     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.5.3110     Document Type: Article

References (36)

1. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
2. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde, and D. Beach. 1995. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
3. Ikeda, H., N. Ohta, K. Furukawa, H. Miyazaki, L. Wang, K. Kuribayashi, L. J. Old, and H. Shiku. 1997. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA 94: 6375-6379.
4. + T cell adoptive immunotherapy. Immunity 13: 265-276.
5. Schreiber, H. 1993. Tumor immunology. In Fundamental Immunology, 3rd Ed. W.E. Paul, ed. Raven Press, New York. p. 1143-1178.
6. Sogn, J. A. 1998. Tumor immunology: the glass is half full. Immunity 9: 757-763.
7. + T cells. J. Exp. Med. 198: 569-580.
8. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161: 2187-2194.
9. Ochsenbein, A. F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96: 2233-2238.
10. Nguyen, L. T., A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195: 423-435.
11. + T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162: 2858-2866.
12. + T cell- and IL-2-dependent mechanism. Immunity 11: 483-493.
13. Shi, W., P. Bu, J. Liu, A. Polack, S. Fisher, and L. Qiao. 1999. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol 73: 7877-7881.
14. Shi, W., J. Liu, Y. Huang, and L. Qiao. 2001. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J. Virol. 75: 10139-10148.
15. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747.
16. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
17. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304: 1314-1317.
18. + T cell cross-priming via transfer of proteasome substrates. Science 304: 1318-1321.
19. Tanchot, C., and B. Rocha. 1997, Peripheral selection of T cell repertoires: the role of continuous thymus output. J. Exp. Med. 186: 1099-1106.
20. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251: 1228-1231.
21. Vezys, V., S. Olson, and L. Lefrancois. 2000. Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity 12: 505-514.
22. Chen, L., S. Ashe, W. A. Brady, J. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102.
23. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14: 483-486.
24. + T cells by B7-transfected melanoma cells. Science 259: 368-370.
25. Ranges, G. E., I. S. Figari, T. Espevik, and M. A. Palladino, Jr. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166: 991-998.
26. 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87: 1486-1490.
27. Becker, J. C., C. Czerny, and E. B. Brocker. 1994. Maintenance of clonal anergy by endogenously produced IL-10. Int. Immunol. 6: 1605-1612.
28. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q. J. Zhang, M. G. Masucci, and R. Kiessling. 1994. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J. Exp. Med. 180: 2371-2376.
29. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366.
30. + T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192: 63-75.
31. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77: 4911-4927.
32. + T cells undergo peripheral tolerance. Immunity 17: 73-81.
33. + T cell function during in vivo memory or tolerance induction. Immunity 8: 581-590.
34. Kaech, S. M., S. Hemby, E. Kersh, and R. Ahmed. 2002. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111: 837-851.
35. Bikah, G., R. R. Pogue-Caley, L. J. McHeyzer-Williams, and M. G. McHeyzer-Williams. 2000. Regulating T helper cell immunity through antigen responsiveness and calcium entry. Nat. Immunol. 1: 402-412.
36. + T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163: 102-110.